Compare Biogened SA with Similar Stocks
Dashboard
1
The company is Net-Debt Free
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 8.84% signifying low profitability per unit of shareholders funds
2
High Debt company with Weak Long Term Fundamental Strength
3
Positive results in Jun 26
4
With ROE of 10.30%, it has a very attractive valuation with a 0.96 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
PLN 49 Million (Micro Cap)
9.00
NA
125.00%
0.40
10.30%
1.04
Revenue and Profits:
Net Sales:
31 Million
(Quarterly Results - Jun 2026)
Net Profit:
1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.29%
0%
8.29%
6 Months
-0.51%
0%
-0.51%
1 Year
-26.87%
0%
-26.87%
2 Years
-14.04%
0%
-14.04%
3 Years
21.74%
0%
21.74%
4 Years
40.0%
0%
40.0%
5 Years
118.99%
0%
118.99%
Biogened SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.18%
EBIT Growth (5y)
24.18%
EBIT to Interest (avg)
5.13
Debt to EBITDA (avg)
1.11
Net Debt to Equity (avg)
0.40
Sales to Capital Employed (avg)
1.71
Tax Ratio
33.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.31%
ROE (avg)
8.84%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.96
EV to EBIT
6.73
EV to EBITDA
4.53
EV to Capital Employed
0.97
EV to Sales
0.58
PEG Ratio
4.93
Dividend Yield
135.87%
ROCE (Latest)
14.40%
ROE (Latest)
10.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
30.80
29.30
5.12%
Operating Profit (PBDIT) excl Other Income
5.30
4.00
32.50%
Interest
0.60
0.80
-25.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1.40
1.40
Operating Profit Margin (Excl OI)
131.00%
100.40%
3.06%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 5.12% vs -4.56% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 0.00% vs -12.50% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
113.10
110.90
1.98%
Operating Profit (PBDIT) excl Other Income
12.90
13.90
-7.19%
Interest
2.60
2.50
4.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
4.90
5.80
-15.52%
Operating Profit Margin (Excl OI)
75.70%
88.10%
-1.24%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 1.98% vs 16.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -15.52% vs 13.73% in Dec 2024
About Biogened SA 
Biogened SA
Pharmaceuticals & Biotechnology
Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Company’s product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.
Company Coordinates 
Company Details
Ul. Pojezierska 99 , LODZ None : 91-342
Registrar Details






